Qianhai Health Holdings Limited (0911.HK)
HKD 0.27
(0.0%)
HKD 0.27
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -52.7 Million HKD | 75.11% |
| 2022 | -211.75 Million HKD | -14397.84% |
| 2021 | 1.48 Million HKD | 123.11% |
| 2020 | -6.4 Million HKD | -123.99% |
| 2019 | 26.71 Million HKD | 426.82% |
| 2018 | 5.07 Million HKD | -85.86% |
| 2017 | 35.86 Million HKD | 106.82% |
| 2016 | -525.71 Million HKD | -19.92% |
| 2015 | -438.39 Million HKD | -313.48% |
| 2014 | 205.35 Million HKD | 59.67% |
| 2013 | 128.61 Million HKD | 297.67% |
| 2012 | 32.34 Million HKD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 7.77 Million HKD | 0.0% |
| 2024 Q1 | 7.77 Million HKD | -86.92% |
| 2023 Q3 | 29.7 Million HKD | 126.5% |
| 2023 Q1 | -56.05 Million HKD | 77.87% |
| 2023 FY | -52.7 Million HKD | 75.11% |
| 2023 Q4 | 59.41 Million HKD | 100.0% |
| 2023 Q2 | -112.11 Million HKD | -100.0% |
| 2022 Q4 | -253.31 Million HKD | -100.0% |
| 2022 Q3 | -126.65 Million HKD | -745.94% |
| 2022 Q1 | 9.8 Million HKD | 246.8% |
| 2022 FY | -211.75 Million HKD | -14397.84% |
| 2022 Q2 | 19.6 Million HKD | 100.0% |
| 2021 Q4 | 2.82 Million HKD | 100.0% |
| 2021 FY | 1.48 Million HKD | 123.11% |
| 2021 Q1 | -1.85 Million HKD | 75.89% |
| 2021 Q2 | -3.71 Million HKD | -100.0% |
| 2021 Q3 | 1.41 Million HKD | 138.05% |
| 2020 Q1 | 3.45 Million HKD | -81.47% |
| 2020 Q2 | 6.9 Million HKD | 100.0% |
| 2020 Q3 | -3.85 Million HKD | -155.83% |
| 2020 Q4 | -7.7 Million HKD | -100.0% |
| 2020 FY | -6.4 Million HKD | -123.99% |
| 2019 Q4 | 18.61 Million HKD | 100.0% |
| 2019 Q2 | 8.1 Million HKD | 100.0% |
| 2019 Q1 | 4.05 Million HKD | 215.02% |
| 2019 FY | 26.71 Million HKD | 426.82% |
| 2019 Q3 | 9.3 Million HKD | 14.89% |
| 2018 FY | 5.07 Million HKD | -85.86% |
| 2018 Q4 | -3.52 Million HKD | 0.0% |
| 2018 Q3 | -3.52 Million HKD | -158.14% |
| 2018 Q2 | 6.05 Million HKD | 0.0% |
| 2018 Q1 | 6.05 Million HKD | -31.54% |
| 2017 Q1 | 9.08 Million HKD | 102.29% |
| 2017 FY | 35.86 Million HKD | 106.82% |
| 2017 Q2 | 9.08 Million HKD | 0.0% |
| 2017 Q4 | 8.84 Million HKD | 0.0% |
| 2017 Q3 | 8.84 Million HKD | -2.59% |
| 2016 Q4 | -395.83 Million HKD | -100.0% |
| 2016 Q3 | -197.91 Million HKD | -204.79% |
| 2016 Q2 | -64.93 Million HKD | 0.0% |
| 2016 Q1 | -64.93 Million HKD | 85.19% |
| 2016 FY | -525.71 Million HKD | -19.92% |
| 2015 Q2 | 219.19 Million HKD | 0.0% |
| 2015 Q3 | -438.39 Million HKD | -300.0% |
| 2015 FY | -438.39 Million HKD | -313.48% |
| 2015 Q1 | 219.19 Million HKD | 1390.16% |
| 2015 Q4 | -438.39 Million HKD | 0.0% |
| 2014 Q3 | 14.7 Million HKD | -83.28% |
| 2014 Q1 | 87.96 Million HKD | 522.95% |
| 2014 FY | 205.35 Million HKD | 59.67% |
| 2014 Q4 | 14.7 Million HKD | 0.0% |
| 2014 Q2 | 87.96 Million HKD | 0.0% |
| 2013 Q2 | 50.18 Million HKD | 0.0% |
| 2013 Q4 | 14.12 Million HKD | 0.0% |
| 2013 Q3 | 14.12 Million HKD | -71.86% |
| 2013 Q1 | 50.18 Million HKD | 56.08% |
| 2013 FY | 128.61 Million HKD | 297.67% |
| 2012 FY | 32.34 Million HKD | 0.0% |
| 2012 Q4 | 32.15 Million HKD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 105.03 Million HKD | 150.177% |
| Grand Pharmaceutical Group Limited | 1.87 Billion HKD | 102.803% |
| Extrawell Pharmaceutical Holdings Limited | -162.94 Million HKD | 67.656% |
| Wai Yuen Tong Medicine Holdings Limited | -15.35 Million HKD | -243.221% |
| Lee's Pharmaceutical Holdings Limited | 16.69 Million HKD | 415.637% |
| Essex Bio-Technology Limited | 275.25 Million HKD | 119.147% |
| Tongfang Kontafarma Holdings Limited | -28.84 Million HKD | -82.731% |
| PuraPharm Corporation Limited | -106.08 Million HKD | 50.316% |
| SSY Group Limited | 1.31 Billion HKD | 103.997% |
| JBM (Healthcare) Limited | 130.46 Million HKD | 140.398% |
| Jacobson Pharma Corporation Limited | 266.96 Million HKD | 119.742% |
| China Resources Pharmaceutical Group Limited | 3.85 Billion HKD | 101.367% |